Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M

By The Northwire Desk — AI Analysis Nov 27, 2025 · 01:34 INNO · 12 InnoCan Pharma Corporation
INNO · Price

Executive Summary

  • Innocan Pharma reported nine‑month (Q3) 2025 revenues of US $21.6 M, a 10% decline versus the same period in 2024.
  • Gross profit fell 10.5% to US $19.5 M, but gross margin remained high at 90.2%.
  • Operating loss was stable at US $0.333 M (up 1.5% from prior year).

Key Details

  • Revenues: US $21.624 M for nine months ended Sep 30 2025 vs. US $24.036 M in 2024 (‑10%).
  • Gross Profit: US $19.501 M vs. US $21.778 M in 2024 (‑10.5%).
  • Gross Margin: 90.2% in 2025 versus 90.6% in 2024.
  • Operating Loss: US $0.333 M in 2025, a 1.5% increase from the US $0.328 M loss recorded in 2024.
  • Management Commentary: CEO Iris Bincovich highlighted encouraging pre‑clinical pharmacokinetic and safety data for LPT‑CBD in minipigs, supporting IND‑enabling studies and future FDA submissions.
  • Business Segments: Consumer Wellness segment continued to show resilience and profitability despite a weak U.S. market; the company remains a 60% shareholder of joint‑venture B.I. Sky Global Ltd.
  • Future Outlook: Company is progressing toward a U.S. public offering and will host an earnings call/Investor update on Thursday, Nov 27 2025 at 1:00 pm EST (Zoom link provided).
  • Access to Full Statements: Unaudited condensed interim consolidated financial statements for three‑ and nine‑month periods are available on the company website and SEDAR+ profile.

Notable Quotes

“The Company continues to deliver strong gross margins, reflecting the strength of our business model and operational execution.” – Iris Bincovich, CEO, Innocan Pharma
“We developed and implemented a strategic response to tariffs and optimized our supply chain, resulting in substantial cost savings and improved gross profit performance.” – Roni Kamhi, CEO of B.I. Sky Global & COO of Innocan Pharma

Materiality Assessment: Material – Neutral (the release contains full quarterly financial results that are material for investors, though the net change is modestly negative on revenue.)

Read the original news release →

More from InnoCan Pharma Corporation

May 27, 2026 · 16:00

Innocan’s Revenue Rebound Is No Match for a Shelved U.S. IPO as Cash Burn Leaves a Bitter Aftertaste

Earnings May 06, 2026 · 16:01

Innocan Pharma Shares Tumble 73% as Revenue Slips; Media Feature Fails to Halt Downtrend

Other Apr 06, 2026 · 06:52

Innovating drug delivery for chronic pain solutions

Financings Mar 31, 2026 · 20:03

Innocan arranges $200,000 (U.S.) debenture offering

Financings Mar 31, 2026 · 10:20

[Value]

Financings Mar 31, 2026 · 03:00

Insider Debt Bridges Runway as Core Revenue Slips Ahead of Uncertain U.S. Uplisting

Earnings